Dear shareholders and prospective shareholders,
In August, we were busy building awareness for the CRH O’Regan System at a number of gastroenterology conferences. First, we attended a GI Outlook meeting hosted by the American Society for Gastrointestinal Endoscopy in Washington, DC. The meeting focused on practice management and enabled us to communicate with a number of managerial office staff as well as physicians.
We also attended the American College of Gastroenterology’s Midwest Regional Course in Indianapolis, IN where we connected with a number of trained physicians as well as new GIs – who were considering introducing CRH’s hemorrhoid treatment for the first time.
The conferences were excellent opportunities to reinforce our relationships with those in the GI community as well as reconnect with physicians utilizing the CRH O’Regan System.
Annual Survey Results
In August, CRH sent out our annual survey to physicians and staff who are trained on the CRH O’Regan System. The purpose of the survey is to determine what is of value to our customers – ensuring that CRH is meeting their needs, and most importantly, to engage with our customers and reiterate our value propositions.
The responses and feedback were very positive overall, with some of the “take-aways” being the following: most physicians indicated they’ll be performing more banding procedures through 2014; ease of use and efficiency of the O’Regan System were the top reasons for providing the procedure; and continued satisfaction for the on-going support received from the company was very much appreciated.
Fall and Early Winter Marketing
Looking ahead, we intend to market the story frequently in the coming months to audiences we believe will be highly receptive to the CRH Medical story.
For example, we plan to be in financial centres such as Vancouver, Toronto, Montreal and New York, visiting with buy and sell side accounts that have a demonstrated appetite for profitable, small cap growth companies such as CRH Medical.
We are looking forward to talking about our market opportunity and how the CRH O’Regan System – a safe and efficacious treatment for hemorrhoids – is steadily gaining market share.
We look forward to sharing the September edition of the CRH Investor Bulletin with you, and as always, we appreciate your interest and support.
Media and Investor Relations
416.815.0700 x 225